Pharsight

Drug Patents Expiring in 2019

1. Adempas patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6743798 BAYER HLTHCARE Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
Jul, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Oct 08, 2020
New Chemical Entity Exclusivity(NCE) Oct 08, 2018
Orphan Drug Exclusivity(ODE-53) Oct 08, 2020

Drugs and Companies using RIOCIGUAT ingredient

NCE-1 date: 08 October, 2017

Market Authorisation Date: 08 October, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ADEMPAS before it's drug patent expiration?
More Information on Dosage

ADEMPAS family patents

Family Patents

2. Brilinta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7250419 ASTRAZENECA Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Dec, 2019

(4 years ago)

US6525060 ASTRAZENECA Triazolo(4,5-d)pyrimidine compounds
Dec, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-848) Nov 05, 2023
M(M-283) May 09, 2025
Pediatric Exclusivity(PED) Nov 09, 2025
New Indication(I-851) May 28, 2023
New Strength(NS) Sep 03, 2018
New Indication(I-714) Sep 03, 2018
New Chemical Entity Exclusivity(NCE) Jul 20, 2016

Drugs and Companies using TICAGRELOR ingredient

NCE-1 date: 09 November, 2024

Market Authorisation Date: 03 September, 2015

Treatment: Treatment of thrombotic stroke; Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Duavee patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5998402 WYETH PHARMS 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
Apr, 2019

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 13, 2018
New Product(NP) Oct 03, 2016

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

NCE-1 date: 13 October, 2017

Market Authorisation Date: 03 October, 2013

Treatment: Prevention of postmenopausal osteoporosis

Dosage: TABLET;ORAL

More Information on Dosage

DUAVEE family patents

Family Patents

4. Gilenya patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5604229 NOVARTIS 2-amino-1,3-propanediol compound and immunosuppressant
Feb, 2019

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) May 11, 2021
New Patient Population(NPP) May 11, 2021
Pediatric Exclusivity(PED) Nov 11, 2021
M(M-106) Jul 20, 2014
New Chemical Entity Exclusivity(NCE) Sep 21, 2015

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

NCE-1 date: 11 November, 2020

Market Authorisation Date: 11 May, 2018

Treatment: Treatment of autoimmune disease

Dosage: CAPSULE;ORAL

How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage

GILENYA family patents

Family Patents

5. Jadenu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6465504 NOVARTIS PHARMS CORP Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Apr, 2019

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-241) Jul 24, 2022
Orphan Drug Exclusivity(ODE) Jan 23, 2020
M(M-239) Dec 12, 2021
Orphan Drug Exclusivity(ODE-39) Jan 23, 2020
M(M-263) Jul 23, 2023

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 30 March, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JADENU before it's drug patent expiration?
More Information on Dosage

JADENU family patents

Family Patents

6. Jadenu Sprinkle patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6465504 NOVARTIS Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Apr, 2019

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-241) Jul 24, 2022
M(M-239) Dec 12, 2021
M(M-263) Jul 23, 2023

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 18 May, 2017

Treatment: NA

Dosage: GRANULE;ORAL

More Information on Dosage

JADENU SPRINKLE family patents

Family Patents

7. Juluca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7067522 VIIV HLTHCARE 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
Dec, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 12, 2018
New Combination(NC) Nov 21, 2020

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 21 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage

JULUCA family patents

Family Patents

8. Levemir Flextouch patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5750497 NOVO NORDISK INC Acylated insulin
Jun, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-117) May 18, 2015
M(M-115) Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

LEVEMIR FLEXTOUCH family patents

Family Patents

9. Lexiscan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47351 ASTELLAS 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
Jun, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-194) Jan 17, 2020
New Chemical Entity Exclusivity(NCE) Apr 10, 2013

Drugs and Companies using REGADENOSON ingredient

NCE-1 date: 10 April, 2012

Market Authorisation Date: 10 April, 2008

Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEXISCAN before it's drug patent expiration?
More Information on Dosage

LEXISCAN family patents

Family Patents

10. Lumason patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5686060 BRACCO Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography
Nov, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-728) Mar 31, 2019
New Chemical Entity Exclusivity(NCE) Oct 10, 2019
New Patient Population(NPP) Nov 13, 2022

Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient

NCE-1 date: 10 October, 2018

Market Authorisation Date: 15 October, 2014

Treatment: NA

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage

LUMASON family patents

Family Patents

11. Nerlynx patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6288082 PUMA BIOTECH Substituted 3-cyanoquinolines
Sep, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-182) Jun 28, 2024
New Chemical Entity Exclusivity(NCE) Jul 17, 2022
New Indication(I-823) Feb 25, 2023

Drugs and Companies using NERATINIB MALEATE ingredient

NCE-1 date: 17 July, 2021

Market Authorisation Date: 17 July, 2017

Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy

Dosage: TABLET;ORAL

How can I launch a generic of NERLYNX before it's drug patent expiration?
More Information on Dosage

NERLYNX family patents

Family Patents

12. Noxafil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5661151 MERCK SHARP DOHME Tetrahydrofuran antifungals
Jul, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 31, 2024
Orphan Drug Exclusivity(ODE-355) Jun 17, 2028
New Indication(I-881) Jun 17, 2024

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 25 November, 2013

Treatment: Prophylaxis of invasive aspergillus and candida infections

Dosage: TABLET, DELAYED RELEASE;ORAL; SOLUTION;INTRAVENOUS

How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage

NOXAFIL family patents

Family Patents

13. Odefsey patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7067522 GILEAD SCIENCES INC 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
Dec, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
M(M-207) Aug 21, 2020
M(M-206) Aug 21, 2020

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 01 March, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage

ODEFSEY family patents

Family Patents

14. Rapivab patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6503745 BIOCRYST Cyclopentane and cyclopentene compounds and use for detecting influenza virus
Nov, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 20, 2020
New Chemical Entity Exclusivity(NCE) Dec 19, 2019

Drugs and Companies using PERAMIVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 19 December, 2014

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

RAPIVAB family patents

Family Patents

15. Revlimid patents expiration

Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5635517 BRISTOL MYERS SQUIBB Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
Oct, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-131) Feb 22, 2024
Orphan Drug Exclusivity(ODE-241) May 28, 2026
Orphan Drug Exclusivity(ODE-245) May 28, 2026
New Indication(I-706) Feb 17, 2018
New Indication(I-796) May 28, 2022
New Indication(I-797) May 28, 2022
Orphan Drug Exclusivity(ODE-49) Jun 05, 2020
Orphan Drug Exclusivity(ODE-88) Feb 17, 2022
New Indication(I-672) Jun 05, 2016
Orphan Drug Exclusivity(ODE) Jun 05, 2020
New Strength(NS) Jun 05, 2016

Drugs and Companies using LENALIDOMIDE ingredient

Market Authorisation Date: 21 December, 2011

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage

REVLIMID family patents

Family Patents

16. Selzentry patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6586430 VIIV HLTHCARE CCR5 modulators
Dec, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 28, 2013
New Strength(NS) Nov 04, 2019
New Chemical Entity Exclusivity(NCE) Aug 06, 2012

Drugs and Companies using MARAVIROC ingredient

NCE-1 date: 07 August, 2011

Market Authorisation Date: 04 November, 2016

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: TABLET;ORAL; SOLUTION;ORAL

How can I launch a generic of SELZENTRY before it's drug patent expiration?
More Information on Dosage

SELZENTRY family patents

Family Patents

17. Synribo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE45128 TEVA PHARMS INTL Cephalotaxane derivatives and their processes of preparation and purification
Mar, 2019

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-32) Oct 26, 2019
New Chemical Entity Exclusivity(NCE) Oct 26, 2017
Orphan Drug Exclusivity(ODE) Oct 26, 2019

Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient

NCE-1 date: 26 October, 2016

Market Authorisation Date: 26 October, 2012

Treatment: Treatment of leukemia

Dosage: POWDER;SUBCUTANEOUS

How can I launch a generic of SYNRIBO before it's drug patent expiration?
More Information on Dosage

SYNRIBO family patents

Family Patents

18. Torisel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44768 PF PRISM CV Rapamycin hydroxyesters
Feb, 2019

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) May 30, 2015
M(M-92) Jul 09, 2013
Orphan Drug Exclusivity(ODE) May 30, 2014
M(M-91) Apr 26, 2013
Pediatric Exclusivity(PED) Jan 09, 2014

Drugs and Companies using TEMSIROLIMUS ingredient

Market Authorisation Date: 30 May, 2007

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of TORISEL before it's drug patent expiration?
More Information on Dosage

TORISEL family patents

Family Patents

19. Tykerb patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513262 NOVARTIS Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
Jan, 2019

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-235) Dec 06, 2021
New Chemical Entity Exclusivity(NCE) Mar 13, 2012
New Indication(I-620) Jan 29, 2013

Drugs and Companies using LAPATINIB DITOSYLATE ingredient

NCE-1 date: 14 March, 2011

Market Authorisation Date: 13 March, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TYKERB before it's drug patent expiration?
More Information on Dosage

TYKERB family patents

Family Patents

List of large molecules

1. List of Actemra large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US5795965 NA Reshaped human to human interleukin-6 receptor
Apr, 2019

(5 years ago)

Ingredients: TOCILIZUMAB

2. List of Iplex large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US5681818 NA Therapeutic uses of human somatomedin carrier proteins
May, 2019

(5 years ago)

Ingredients: MECASERMIN RINFABATE [RDNA ORIGINAL INJECTION]

3. List of Levemir large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US5750497 NA Acylated insulin
Jun, 2019

(4 years ago)

Ingredients: INSULIN DETEMIR

4. List of Orencia large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US5851795 NA Soluble CTLA4 molecules and uses thereof
Oct, 2019

(4 years ago)

Ingredients: ABATACEPT

5. List of Nucala large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US5693323 NA Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
Dec, 2019

(4 years ago)

Ingredients: MEPOLIZUMAB